Successful Use of Sirolimus in Children With Large Mesenteric Lymphatic Lesions

J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):e24-e25. doi: 10.1097/MPG.0000000000001703.

Authors

Swellen Gastineau¹, Giulia Paolella², Cécile Talbotec³, Virginie Verkarre⁴, Frédérique Sauvat⁵, Olivier Goulet³, Sylvie Fraitag⁴, Florence Lacaille³

Affiliations

¹ Department of Pediatrics, CHU Hôpital Sud, Rennes, France.
² Department of Pediatrics, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
³ Department of Pediatric Gastroenterology, Hepatology and Nutrition.
⁴ Department of Pathology, Hôpital Universitaire Necker-Enfants malades, Paris.
⁵ Department of Pediatric Surgery, Centre Hospitalier Universitaire de La Réunion, Félix Guyon, Saint-Denis, France.

PMID: 28777125
DOI: 10.1097/MPG.0000000000001703

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Child
Female
Follow-Up Studies
Hemangioendothelioma / drug therapy*
Humans
Infant
Infant, Newborn
Kasabach-Merritt Syndrome / drug therapy*
Lymphangioma, Cystic / drug therapy*
Male
Mesentery
Peritoneal Neoplasms / drug therapy*
Sarcoma, Kaposi / drug therapy*
Sirolimus / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Sirolimus

Supplementary concepts

Kaposiform Hemangioendothelioma